Gastric / GEJ adenocarcinoma · line 1 · Trastuzumab + capecitabine + cisplatin (TOGA / KEYNOTE-811)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-TRASTUZUMAB-CHEMO-TOGA`

ID	`IND-GASTRIC-METASTATIC-1L-HER2-TOGA`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-GASTRIC`
Sources	`SRC-ESMO-GASTRIC-2024` `SRC-NCCN-GASTRIC-2025`

Notes

HER2+ metastatic gastric — primary aggressive track.

Used By

Algorithms

ALGO-GASTRIC-METASTATIC-1L - ALGO-GASTRIC-METASTATIC-1L